making new medical technologies available in Hungary

Stryker’s DAWN Trial results contribute to updated acute ischemic stroke guidelines from the American Heart Association and American Stroke Association

Stryker’s DAWN Trial results contribute to updated acute ischemic stroke guidelines from the American Heart Association and American Stroke Association Kalamazoo, Michigan, USA – January 25, 2018 – Yesterday the American Heart Association and American Stroke Association updated the ischemic...
READ MORE

Synergy Stent with Shorter DAPT is Superior to a Bare-Metal Stent in Elderly Patients

Synergy Stent with Shorter DAPT is Superior to a Bare-Metal Stent in Elderly Patients Results from the SENIOR Trial Reported at TCT 2017 and Published Simultaneously in The Lancet DENVER – November 1, 2017 – Elderly patients undergoing PCI often receive bare-metal stents (BMS) instead of...
READ MORE

Five-year Follow-up Data Demonstrate the WATCHMAN™ Left Atrial Appendage Closure Device Provides Stroke Risk Reduction Comparable to Warfarin Therapy

Five-year Follow-up Data Demonstrate the WATCHMAN™ Left Atrial Appendage Closure Device Provides Stroke Risk Reduction Comparable to Warfarin Therapy Late-breaking Clinical Trial Data Presented at TCT 2017 with Simultaneous Publication in the Journal of the American College of Cardiology Nov 2,...
READ MORE

SYNTAX II: State-of-the-art PCI yields fewer adverse events in de novo three-vessel disease

SYNTAX II: State-of-the-art PCI yields fewer adverse events in de novo three-vessel disease Topic(s): Cardiovascular Surgery Interventional Cardiology and Cardiovascular Surgery In patients with three-vessel disease the use of the SYNTAX II strategy is associated with improved clinical outcomes...
READ MORE

New Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Traditional Clinically-Reported Endpoints

New Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Traditional Clinically-Reported Endpoints Analyses Evaluated the Impact of Ethnicity, Gender and Income on Cardiovascular Outcomes May 12, 2017 NEW ORLEANS and MARLBOROUGH, Mass., May 12...
READ MORE

SYNERGY™ BP Stent Demonstrates Excellent Safety in the EVOLVE II Clinical Trial Outstanding Safety in 18,000 Patients Across 9 Studies

Addressing the Full Spectrum of Cardiovascular Disease Complexity The SYNERGY™ Bioabsorbable Polymer (BP) Stent is being studied in 20 investigator-sponsored research trials including more than 30,000 patients, allowing physicians worldwide to provide data on patients receiving the SYNERGY BP...
READ MORE

Long-term Safety with the SYNERGY Stent System

Long-term Safety with the SYNERGY Stent System EVOLVE II Trial 2-Year Results Dr. Dean Kereiakes highlights the key 2-Year data coming out of the EVOLVE II Trial including exceptionally low ST rates for the SYNERGY Stent System. Source: Boston Scientific
READ MORE

Eluvia™ Drug-eluting Vascular Stent System Demonstrates 12-month Primary Patency Of 96.1 Percent

28 Sep 2015 MAJESTIC Trial Data Support Strong Safety Profile with Low Target Lesion Revascularization Rate MARLBOROUGH, Mass. – New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System reflect a primary...
READ MORE

Boston Scientific receives CE mark for Eluvia™ drug-eluting vascular stent and announces initiation of new clinical trial

22 Feb 2016 First polymer-based, drug-eluting stent designed to treat peripheral lesions above the knee approved in Europe; IMPERIAL trial initiated to seek regulatory approvals in U.S. and Asia Boston Scientific, today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received...
READ MORE